of EDCs prior to conception, during gestation, and 
throughout lactation; 
(2) to prevent harmful exposure to EDCs in 
homes, workplaces, schools, public and private trans-
portation vehicles, indoor and outdoor recreational 
environments, and in drinking water, foods, and con-
sumer products; 
(3) to develop scientific support for Federal 
public health strategies based on the entire body of 
peer-reviewed public literature in an environment 
that is free from conflicts of interest; 
(4) to promote research into endocrine disrup-
tion by encouraging the multidisciplinary, multi-in-
stitutional, and international collaborations that in 
the past have produced many breakthroughs in 
knowledge; 
(5) to create graduate-level scholarships and 
post-doctoral fellowships to train young scientists 
who can meet the demand for technicians and public 
health and health care personnel in endocrine dis-
ruption prevention; 
(6) to determine which chemicals in commerce 
have the potential to disrupt the human endocrine 
system and to remove these chemicals, and products 
containing them, from the market; and 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
(7) to prevent the introduction of new chemi-
cals, and products containing them, that have the 
potential to disrupt the human endocrine system by 
requiring testing for these effects before these 
chemicals and products are released on the market. 
SEC. 3. ENDOCRINE DISRUPTION PREVENTION PROGRAM. 
Subpart 12 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 2851 et seq.) is amended by adding 
at the end the following: 
‘‘SEC. 463C. ENDOCRINE DISRUPTION PREVENTION. 
‘‘(a) PROGRAM.—The Director of the National Insti-
tute of Environmental Health Sciences shall establish a 
program, to be known as the Endocrine Disruption Pre-
vention Program, consisting of research, workshops, and 
fora under subsection (b). 
‘‘(b) RESEARCH, WORKSHOPS, AND FORA.— 
‘‘(1) RESEARCH.—The Director of the Institute 
shall conduct and support multidisciplinary research, 
to improve the understanding of endocrine disrup-
tion. Such research shall— 
‘‘(A) include research to design and de-
velop sensitive tests to screen chemicals using 
assays that are effective for identifying chemi-
cals with the potential to disrupt the human en-
docrine system; 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(B) address the full range of possible 
health outcomes, including— 
‘‘(i) male and female developmental 
and reproductive disorders; 
‘‘(ii) brain (behavioral and intellec-
tual) disorders; 
‘‘(iii) metabolic syndrome, pre-diabe-
tes, diabetes, improper glucose and fat me-
tabolism, obesity, and cardiovascular dis-
orders; 
‘‘(iv) 
effects 
on 
the 
pituitary, 
hypothalamus, hippocampus, thyroid, adre-
nal, immune, bone, cardiovascular, and 
other 
endocrine 
organs 
and 
systems 
throughout all life stages; 
‘‘(v) hormonally driven cancer; and 
‘‘(vi) other related effects; 
‘‘(C) be appropriately sensitive to detect a 
chemical’s potential to disrupt the human endo-
crine system at ambient exposure dosing levels; 
‘‘(D) consider the potential for additive 
and synergistic effects and need not be based 
solely on expectations of monotonic effects 
where the dose reflects the toxicity; 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(E) be carried out using a multidisci-
plinary approach to assure connections among 
multiple levels, from molecular to organ to 
whole animal or human research; and 
‘‘(F) be designed to develop biomarkers of 
exposure and effect that can be further devel-
oped and translated for use in human epidemio-
logical and public health studies focused on de-
fining the role of endocrine disrupting chemicals 
in disease etiology across the lifespan. 
‘‘(2) WORKSHOPS AND FORA.— 
‘‘(A) IN GENERAL.—The Director of the 
Institute shall conduct workshops and fora on 
the health effects associated with environmental 
agents that may affect the endocrine system in 
order to— 
‘‘(i) identify new chemicals of concern 
for research under paragraph (1); 
‘‘(ii) strategize on approaches for the 
development of sensitive tests to screen 
chemicals for endocrine disrupting activity 
using assays; 
‘‘(iii) review the state of the science 
and provide recommendations for a re-
search, testing, and training agenda; and 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(iv) educate attendees about endo-
crine disrupting chemicals. 
‘‘(B) WORKSHOPS.— 
‘‘(i) FIRST WORKSHOP.—The Director 
of the Institute shall invite the Secretary 
of the Interior, the Administrator of the 
Environmental Protection Agency, and the 
Director of the Centers for Disease Control 
and Prevention to participate in a work-
shop under subparagraph (A) not later 
than 150 days after the date of the enact-
ment of this section. 
‘‘(ii) SUBSEQUENT WORKSHOPS.—The 
Director of the Institute shall convene sub-
sequent workshops under subparagraph 
(A) as the Director determines appro-
priate. 
‘‘(iii) PARTICIPANTS.—The Director 
of the Institute shall— 
‘‘(I) invite additional participants 
to each workshop under subparagraph 
(A); 
‘‘(II) in selecting such partici-
pants, include scientists and health 
professionals who are knowledgeable 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
about the endocrine system and envi-
ronmental exposures that may influ-
ence the endocrine system; 
‘‘(III) select as participants only 
those individuals who the Director de-
termines will participate in a manner 
free of conflicts of interest; and 
‘‘(IV) in addition to the partici-
pants invited under subclause (I), 
allow representatives of nongovern-
mental organizations to attend each 
workshop under subparagraph (A) as 
observers. 
‘‘(C) FORA.—At least every 3 years, the 
Director of the Institute shall convene an open 
forum for all stakeholders— 
‘‘(i) to review the state of the science 
relevant to environmental agents that in-
fluence the endocrine system; and 
‘‘(ii) to discuss the future direction of 
the Endocrine Disruption Prevention Pro-
gram. 
‘‘(c) EXPERT PANEL.— 
‘‘(1) ESTABLISHMENT.—The Director of the 
Institute shall establish an Endocrine Disruption 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
Program Panel (in this section referred to as the 
‘Panel’) not later than one year after the date of the 
enactment of this section. 
‘‘(2) MEMBERS.—The Director of the Institute 
shall appoint the members of the Panel from among 
individuals who— 
‘‘(A) have established expertise in the field 
of endocrine disruption research by publishing 
research in peer-reviewed literature; 
‘‘(B) provide assurances they will perform 
their duties in a manner free of conflicts of in-
terest (as determined by the Director), includ-
ing by complying with section 208 of title 18, 
United States Code; and 
‘‘(C) represent diverse disciplines, includ-
ing developmental biology, endocrinology, devel-
opmental and neurological biology, embryology, 
biochemistry, physiology, epidemiology, endo-
crine driven oncology, and medical research. 
‘‘(3) DUTIES.—The Panel shall— 
‘‘(A) provide advice to the Director of the 
Institute on the conduct and support of re-
search under subsection (b); 
‘‘(B) evaluate existing population-level bio-
monitoring and biobanking surveillance and re-
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
search programs and recommend changes need-
ed to develop data on human exposures and ef-
fects to support the Endocrine Disruption Pre-
vention Program; and 
‘‘(C) develop a list of chemicals of concern 
for endocrine disruption effects and make find-
ings with respect to such chemicals in accord-
ance with paragraph (4). 
‘‘(4) CHEMICALS OF CONCERN.— 
‘‘(A) LIST.—The Panel shall— 
‘‘(i) develop a list of chemicals of con-
cern for endocrine disruption effects; and 
‘‘(ii) update such list annually. 
‘‘(B) 
QUALITATIVE
EVALUATION
SYS-
TEM.—The Panel shall create a tiered quali-
tative evaluation system, modeled after that of 
the National Toxicology Program, in order to 
express the Panel’s level of concern that a 
chemical on the list under subparagraph (A) 
has the potential to disrupt the human endo-
crine system. 
‘‘(C) REQUIRED
FINDINGS.—For each 
chemical identified in the list under subpara-
graph (A), the Panel shall review peer-reviewed 
studies and other relevant data and issue a 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
finding, based on all of the available evidence, 
regarding— 
‘‘(i) the level of the Panel’s concern, 
under the tiered qualitative evaluation sys-
tem, that the chemical has the potential to 
disrupt the human endocrine system; 
‘‘(ii) the need for additional data to 
determine the level of concern associated 
with the chemical’s potential to disrupt the 
human endocrine system; or 
‘‘(iii) the need for assays to be devel-
oped to provide the data necessary to sup-
port a determination as to the level of con-
cern associated with the chemical’s poten-
tial to disrupt the human endocrine sys-
tem. 
‘‘(D) SUFFICIENT
DATA.—If the Panel 
finds under subparagraph (C)(i) that data are 
sufficient to determine the extent to which a 
chemical has the potential to disrupt the human 
endocrine system, the Panel shall publish an ex-
planation of this determination and include the 
supporting data. 
‘‘(E) MINIMAL
LEVEL
OF
CONCERN.—If 
the Panel finds under subparagraph (C)(i) that 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
data are sufficient to determine (under the 
tiered qualitative evaluation system established 
under subparagraph (B)) that there is at least 
a minimal level of concern associated with a 
chemical’s potential to disrupt the human endo-
crine system, the Panel shall describe the routes 
and sources of exposure to the chemical that 
may cause effects to human health. 
‘‘(F) ADDITIONAL DATA NEEDED.—If the 
Panel finds under subparagraph (C)(ii) that ad-
ditional data are needed to determine the level 
of concern associated with the chemical’s poten-
tial to disrupt the human endocrine system, the 
Panel shall— 
‘‘(i) identify such data; and 
‘‘(ii) recommend a process for devel-
oping such data directly or by grant or 
contract. 
‘‘(G) ASSAYS NEEDED.—If the Panel finds 
under subparagraph (C)(iii) that assays need to 
be developed to provide the data necessary to 
support a determination as to the level of con-
cern associated with the chemical’s potential to 
disrupt the human endocrine system, the Panel 
shall identify such assays to the extent possible. 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(H) ANNUAL REPORT.—The Panel shall 
submit to the Director of the Institute and to 
the Congress an annual report on the Panel’s 
activities. Each such report shall include— 
‘‘(i) an updated version of the list de-
veloped under subparagraph (A); and 
‘‘(ii) for each chemical on the list, the 
findings and recommendations of the Panel 
under subparagraphs (D) through (G). 
‘‘(I) NO JUDICIAL REVIEW.—A finding or 
other determination of the Panel under this 
paragraph shall not be subject to judicial re-
view, nor to correction under section 515 of the 
Treasury and General Government Appropria-
tions Act, 2001 (commonly referred to as the 
‘Information Quality Act’). 
‘‘(J) PETITIONS.— 
‘‘(i) IN GENERAL.—Any person may 
petition the Panel to determine whether a 
chemical should be listed pursuant to sub-
paragraph (A) or revise a finding or other 
determination under this paragraph based 
on new information. 
‘‘(ii) 
RULES.—The 
Director 
shall 
adopt rules that provide for— 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(I) the form and procedure for 
filing of petitions under this subpara-
graph; and 
‘‘(II) the procedural rights of 
persons filing such petitions. 
‘‘(d) TRANSMISSION
OF
CERTAIN
FINDINGS
TO 
OTHER AGENCIES.— 
‘‘(1) IN GENERAL.—If the Panel finds under 
subsection (c)(4)(C)(i) that data are sufficient to de-
termine (under the tiered qualitative evaluation sys-
tem established under subsection (c)(4)(B)) that 
there is at least a minimal level of concern associ-
ated with a chemical’s potential to disrupt the 
human endocrine system, the Director of the Insti-
tute shall transmit the finding, including the Panel’s 
description of the routes and sources of exposure to 
the chemical and any other relevant information, to 
each Federal agency with authority to regulate the 
chemical or the route or source of human exposure 
to the chemical. 
‘‘(2) PUBLIC AVAILABILITY.—Whenever the Di-
rector of the Institute transmits to one or more 
agencies a finding under paragraph (1) regarding a 
chemical, the Director shall publish in the Federal 
Register the names of the agencies and the chemical. 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
‘‘(e) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there are authorized to be appro-
priated such sums as may be necessary for fiscal years 
2011 through 2021.’’. 
SEC. 4. FEDERAL AGENCY ACTION. 
(a) REQUIREMENTS.—Upon receipt of a transmission 
under section 463C(d) of the Public Health Service Act, 
as added by section 3 of this Act, containing a finding 
that there is at least a minimal level of concern associated 
with a chemical’s potential to disrupt the human endocrine 
system, a Federal agency— 
(1) not later than 180 days after the date of 
such receipt, shall issue a reply in writing to the Di-
rector of the National Institute of Environmental 
Health Sciences (in this Act referred to as the ‘‘In-
stitute’’) describing— 
(A) the agency’s authorities in connection 
with the chemical; 
(B) any past or ongoing actions taken by 
the agency in connection with the chemical; and 
(C) the proposed course of action to be 
taken by the agency in response to the Panel’s 
finding, including but not limited to further 
testing by the Institute or the issuance of regu-
lations, orders, or public notices under the 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
agency’s existing authorities, in furtherance of 
protecting human health from the potential en-
docrine disruption effects of exposure to the 
chemical; and 
(2) not later than one year after the date of 
such receipt, shall submit to the Congress and shall 
publish a report summarizing the actions taken by 
the agency in response to the Panel’s finding, as well 
as proposed future actions to be taken by the agen-
cy. 
(b) NO ADDITIONAL REGULATORY AUTHORITY.— 
This section does not vest any agency with additional au-
thority to regulate a chemical or the route or source of 
human exposure to a chemical. 
(c) CITIZEN SUITS.— 
(1) AUTHORITY TO BRING CIVIL ACTIONS.—Any 
person may commence a civil action to compel any 
agency action required by subsection (a). 
(2) JURISDICTION.—The United States courts 
of appeals shall have exclusive original jurisdiction 
over such an action. 
SEC. 5. TRAINING IN FIELDS RELATED TO THE PREVEN-
TION OF ENDOCRINE DISRUPTION. 
(a) IN GENERAL.—The Director of the Institute shall 
establish a program to support, directly or by making 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS
grants, graduate and postdoctoral training in fields related 
to the prevention of endocrine disruption. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
$2,500,000 for fiscal year 2011 and such sums as may 
be necessary for fiscal years 2012 through 2021. 
Æ 
VerDate Nov 24 2008 
00:08 Dec 04, 2009
Jkt 089200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6301
E:\BILLS\H4190.IH
H4190
tjames on DSKG8SOYB1PROD with BILLS